BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

541 related articles for article (PubMed ID: 25996827)

  • 1. Severe gastrointestinal toxicity with administration of trametinib in combination with dabrafenib and ipilimumab.
    Minor DR; Puzanov I; Callahan MK; Hug BA; Hoos A
    Pigment Cell Melanoma Res; 2015 Sep; 28(5):611-2. PubMed ID: 25996827
    [No Abstract]   [Full Text] [Related]  

  • 2. Fatherhood during dabrafenib and trametinib therapy for metastatic melanoma.
    Cocorocchio E; Pala L; Battaglia A; Gandini S; Peccatori FA; Ferrucci PF
    Acta Oncol; 2018 Aug; 57(8):1131-1133. PubMed ID: 29526130
    [No Abstract]   [Full Text] [Related]  

  • 3. Improved overall survival in melanoma with combined dabrafenib and trametinib.
    Robert C; Karaszewska B; Schachter J; Rutkowski P; Mackiewicz A; Stroiakovski D; Lichinitser M; Dummer R; Grange F; Mortier L; Chiarion-Sileni V; Drucis K; Krajsova I; Hauschild A; Lorigan P; Wolter P; Long GV; Flaherty K; Nathan P; Ribas A; Martin AM; Sun P; Crist W; Legos J; Rubin SD; Little SM; Schadendorf D
    N Engl J Med; 2015 Jan; 372(1):30-9. PubMed ID: 25399551
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fatal gastrointestinal toxicity with ipilimumab after BRAF/MEK inhibitor combination in a melanoma patient achieving pathological complete response.
    Gonzalez-Cao M; Boada A; Teixidó C; Fernandez-Figueras MT; Mayo C; Tresserra F; Bustamante J; Viteri S; Puertas E; Santarpia M; Riso A; Barron F; Karachaliou N; Rosell R
    Oncotarget; 2016 Aug; 7(35):56619-56627. PubMed ID: 27447748
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Brugada syndrome induced by BRAF and MEK inhibitors in a melanoma patient.
    Nardin C; Colas M; Badoz M; Roche-Kubler B; Meneveau N; Puzenat E; Aubin F
    Eur Heart J; 2017 Jul; 38(27):2151. PubMed ID: 28329154
    [No Abstract]   [Full Text] [Related]  

  • 6. Prospective Case Series of Cutaneous Adverse Effects Associated With Dabrafenib and Trametinib.
    Lacroix JP; Wang B
    J Cutan Med Surg; 2017; 21(1):54-59. PubMed ID: 27624900
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Development of serous retinopathy during therapy of a metastatic cutaneous melanoma].
    Lüdeke I; Terheyden P; Grisanti S; Lüke M
    Ophthalmologe; 2016 Oct; 113(10):861-863. PubMed ID: 26873702
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Posterior reversible encephalopathy syndrome in a melanoma patient with dabrafenib and trametinib treatment following immunotherapy.
    Stefanou MI; Gepfner-Tuma I; Brendle C; Kowarik M; Meiwes A; Eigentler T; Müller A; Garbe C; Ziemann U; Tabatabai G; Forschner A
    J Dtsch Dermatol Ges; 2020 Feb; 18(2):136-139. PubMed ID: 31814289
    [No Abstract]   [Full Text] [Related]  

  • 9. Health-related quality of life impact in a randomised phase III study of the combination of dabrafenib and trametinib versus dabrafenib monotherapy in patients with BRAF V600 metastatic melanoma.
    Schadendorf D; Amonkar MM; Stroyakovskiy D; Levchenko E; Gogas H; de Braud F; Grob JJ; Bondarenko I; Garbe C; Lebbe C; Larkin J; Chiarion-Sileni V; Millward M; Arance A; Mandalà M; Flaherty KT; Nathan P; Ribas A; Robert C; Casey M; DeMarini DJ; Irani JG; Aktan G; Long GV
    Eur J Cancer; 2015 May; 51(7):833-40. PubMed ID: 25794603
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Induced sarcoid-like reactions in patients with metastatic melanoma treated with dabrafenib and trametinib: a monocentric retrospective study.
    Huynh S; Lheure C; Franck N; Goldman-Lévy G; Aractingi S; Dupin N; Kramkimel N; Guégan S
    Melanoma Res; 2020 Jun; 30(3):317-320. PubMed ID: 32053122
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Facing the challenges of new melanoma-targeted therapies: Treatment of severe fevers associated with dabrafenib/trametinib combination therapy.
    Lindsay JN; Barras M
    J Oncol Pharm Pract; 2015 Aug; 21(4):293-5. PubMed ID: 24664475
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomised trial.
    Grob JJ; Amonkar MM; Karaszewska B; Schachter J; Dummer R; Mackiewicz A; Stroyakovskiy D; Drucis K; Grange F; Chiarion-Sileni V; Rutkowski P; Lichinitser M; Levchenko E; Wolter P; Hauschild A; Long GV; Nathan P; Ribas A; Flaherty K; Sun P; Legos JJ; McDowell DO; Mookerjee B; Schadendorf D; Robert C
    Lancet Oncol; 2015 Oct; 16(13):1389-98. PubMed ID: 26433819
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hair and nail adverse events during treatment with targeted therapies for metastatic melanoma.
    Dika E; Patrizi A; Ribero S; Fanti PA; Starace M; Melotti B; Sperandi F; Piraccini BM
    Eur J Dermatol; 2016 Jun; 26(3):232-9. PubMed ID: 27019511
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cardiac tamponade induced by dabrafenib and trametinib combination therapy for melanoma: Case report.
    Sundaram VR; Abbas T
    Medicine (Baltimore); 2018 Nov; 97(44):e12751. PubMed ID: 30383630
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma.
    Robert C; Grob JJ; Stroyakovskiy D; Karaszewska B; Hauschild A; Levchenko E; Chiarion Sileni V; Schachter J; Garbe C; Bondarenko I; Gogas H; Mandalá M; Haanen JBAG; Lebbé C; Mackiewicz A; Rutkowski P; Nathan PD; Ribas A; Davies MA; Flaherty KT; Burgess P; Tan M; Gasal E; Voi M; Schadendorf D; Long GV
    N Engl J Med; 2019 Aug; 381(7):626-636. PubMed ID: 31166680
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Acneiform eruptions: a common cutaneous toxicity of the MEK inhibitor trametinib.
    Anforth R; Liu M; Nguyen B; Uribe P; Kefford R; Clements A; Long GV; Fernandez-Peñas P
    Australas J Dermatol; 2014 Nov; 55(4):250-4. PubMed ID: 24313958
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dabrafenib and trametinib, alone and in combination for BRAF-mutant metastatic melanoma.
    Menzies AM; Long GV
    Clin Cancer Res; 2014 Apr; 20(8):2035-43. PubMed ID: 24583796
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Granulomatous nephritis and dermatitis in a patient with BRAF V600E mutant metastatic melanoma treated with dabrafenib and trametinib.
    Jansen YJ; Janssens P; Hoorens A; Schreuer MS; Seremet T; Wilgenhof S; Neyns B
    Melanoma Res; 2015 Dec; 25(6):550-4. PubMed ID: 26512791
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Trametinib-Associated Bradycardia.
    Alhazmi L; Karim MM; Al-Sarie M; Skeel R; Karim S
    Am J Ther; 2019; 26(5):e657-e659. PubMed ID: 31241492
    [No Abstract]   [Full Text] [Related]  

  • 20. Histiocytoid Sweet's syndrome during combined therapy with BRAF and MEK inhibitors for metastatic melanoma.
    Morgado-Carrasco D; Moreno-Rivera N; Fustà-Novell X; García-Herrera A; Carrera C; Puig S
    Melanoma Res; 2018 Jun; 28(3):256-257. PubMed ID: 29683894
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 28.